Company Profile

Vitro Diagnostics, Inc., doing business as Vitro Biopharma, is engaged in the development, manufacturing and distribution of stem cell products and related tools for use in research, drug discovery and clinical trials. The Company's clinical products include clinical grade MSC-Gro for mesenchymal stem cell (MSC) expansion prior to transplantation; an equine MSC cell line with application to treatment of skeletal muscular conditions, such as tendonitis, ligament injury, osteoarthritis and accelerated bone fracture healing, and others; testing and therapies related to endogenous stem cell activation; diagnostic testing of stem cell activation and determination of stem cell functional status, and cell-based assays for discovery of stem cell activation agents and new drugs for the treatment of osteoporosis. The Company offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells.

Employees

Sector

Pharmaceuticals

More about the company

06-15	Vitro Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026	CI
03-16	Vitro Biopharma, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2026	CI
02-13	Vitro Biopharma, Inc. Reports Earnings Results for the Full Year Ended October 31, 2025	CI
12/09/25	Vitro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2025	CI
20/06/25	Vitro Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2025	CI
27/05/25	Vitro Biopharma, Inc. announced a financing transaction	CI
20/03/25	Vitro Biopharma, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2025	CI
28/01/25	Vitro Biopharma, Inc. Reports Earnings Results for the Full Year Ended October 31, 2024	CI
28/01/25	Vitro Biopharma, Inc. Auditor Raises 'Going Concern' Doubt	CI
16/09/24	Vitro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2024	CI
31/05/24	Vitro Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024	CI
13/05/24	Vitro Biopharma, Inc. announced that it has received $0.3 million in funding	CI
11/04/24	Vitro Biopharma, Inc. announced that it has received $0.175 million in funding	CI

06/10/20	VITRO DIAGNOSTICS INC : Regulation FD Disclosure (form 8-K)	AQ
05/10/20	VITRO DIAGNOSTICS INC : Other Events (form 8-K)	AQ
14/07/20	Vitro Diagnostics : Biopharma 2nd Quarter ended April 30th 2020 Financial Results of Operations	AQ
09/07/20	VITRO DIAGNOSTICS INC : Regulation FD Disclosure (form 8-K)	AQ
04/06/20	VITRO DIAGNOSTICS INC : Entry into a Material Definitive Agreement, Regulation FD Disclosure (form 8-K)	AQ

Manager	Title	Age	Since
Christopher Furman CEO	Chief Executive Officer	55	01/07/2022
James Musick CEO	Chief Executive Officer	77	31/03/1986
Thomas Ohrt DFI	Director of Finance/CFO	70	22/01/2024

Director	Title	Age	Since
James Musick CHM	Chairman	77	01/09/1989
Christopher Furman BRD	Director/Board Member	55	01/07/2022
Caroline Mosessian CHM	Chairman	60	01/05/2022

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/11/22 A	Christopher Furman	Other	Chief Executive Officer	0	-
11/11/22 A	Nathan Haas	Other	Chief Financial Officer	4,421,299	-
11/11/22 A	Jack Zamora	Other	Chief Executive Officer	37,049,320	-

Vitro Diagnostics, Inc. Stock

Stocks

VODG

US9285013036

Pharmaceuticals

Latest news: Vitro Diagnostics, Inc.

Press Releases: Vitro Diagnostics, Inc.

Quotes and Performance

Managers and Directors: Vitro Diagnostics, Inc.

Latest insider transactions

Biopharmaceuticals

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VITRO DIAGNOSTICS, INC.	+9.72%	+22.40%	-	-	18.29M
REGENERON PHARMACEUTICALS, INC.	-1.48%	-5.59%	+39.55%	-5.42%	78.04B
MODERNA, INC.	+5.38%	-1.09%	+512.38%	+32.58%	57.48B
CSL LIMITED	+2.68%	-0.93%	-16.09%	-35.72%	57.4B
SAMSUNG BIOLOGICS CO.,LTD.	-0.56%	-2.21%	-11.34%	+27.29%	48.81B
UCB	+0.88%	-1.43%	+0.88%	+151.46%	45.5B
BIOGEN INC.	+0.80%	-1.67%	+49.90%	-15.15%	32.08B
INCYTE CORPORATION	-1.47%	-4.17%	+46.17%	+92.50%	24.62B
INNOVENT BIOLOGICS, INC.	+3.53%	-4.39%	+1.31%	+156.56%	20.77B
SWEDISH ORPHAN BIOVITRUM AB	+1.30%	-1.47%	+62.42%	+97.95%	15.75B
Average	+2.07%	-3.87%	+76.13%	+55.78%	42.27B
Weighted average by Cap.	+1.16%	-3.71%	+91.60%	+37.34%